Minerva Neurosciences, Inc.
NERVDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Roluperidone 32 mg
Negative Symptoms of Schizophrenia
MIN-117 5.0 mg
Major Depressive Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Roluperidone 32 mg | Phase 3 | Negative Symptoms of Schizophrenia | - | - |
MIN-117 5.0 mg | Phase 2 | Major Depressive Disorder | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Minerva Neurosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Minerva Neurosciences, Inc.'s (NERV) pipeline across Phase 3, Phase 2. Its lead program is Roluperidone 32 mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Minerva Neurosciences, Inc.'s next FDA catalyst?→
Minerva Neurosciences, Inc.'s (NERV) next tracked catalyst is a Earnings expected November 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NERV biotech catalysts?→
Add NERV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Minerva Neurosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.